{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:18:14Z","timestamp":1790403494628,"version":"4.1.0"},"reference-count":132,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA162226"],"award-info":[{"award-number":["R01 CA162226"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002192","name":"LUNGevity Foundation","doi-asserted-by":"publisher","award":["P50 CA058187"],"award-info":[{"award-number":["P50 CA058187"]}],"id":[{"id":"10.13039\/100002192","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Eicosanoids represent a family of active biolipids derived from arachidonic acid primarily through the action of cytosolic phospholipase A2-\u03b1. Three major downstream pathways have been defined: the cyclooxygenase (COX) pathway which produces prostaglandins and thromboxanes; the 5-lipoxygenase pathway (5-LO), which produces leukotrienes, lipoxins and hydroxyeicosatetraenoic acids, and the cytochrome P450 pathway which produces epoxygenated fatty acids. In general, these lipid mediators are released and act in an autocrine or paracrine fashion through binding to cell surface receptors. The pattern of eicosanoid production is cell specific, and is determined by cell-specific expression of downstream synthases. Increased eicosanoid production is associated with inflammation and a panel of specific inhibitors have been developed designated non-steroidal anti-inflammatory drugs. In cancer, eicosanoids are produced both by tumor cells as well as cells of the tumor microenvironment. Earlier studies demonstrated that prostaglandin E2, produced through the action of COX-2, promoted cancer cell proliferation and metastasis in multiple cancers. This resulted in the development of COX-2 inhibitors as potential therapeutic agents. However, cardiac toxicities associated with these agents limited their use as therapeutic agents. The advent of immunotherapy, especially the use of immune checkpoint inhibitors has revolutionized cancer treatment in multiple malignancies. However, the majority of patients do not respond to these agents as monotherapy, leading to intense investigation of other pathways mediating immunosuppression in order to develop rational combination therapies. Recent data have indicated that PGE2 has immunosuppressive activity, leading to renewed interest in targeting this pathway. However, little is known regarding the role of other eicosanoids in modulating the tumor microenvironment, and regulating anti-tumor immunity. This article reviews the role of eicosanoids in cancer, with a focus on their role in modulating the tumor microenvironment. While the role of PGE2 will be discussed, data implicating other eicosanoids, especially products produced through the lipoxygenase and cytochrome P450 pathway will be examined. The existence of small molecular inhibitors and activators of eicosanoid pathways such as specific receptor blockers make them attractive candidates for therapeutic trials, especially in combination with novel immunotherapies such as immune checkpoint inhibitors.<\/jats:p>","DOI":"10.3389\/fphar.2020.595498","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T05:39:07Z","timestamp":1605677947000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":124,"title":["Eicosanoids in Cancer: New Roles in Immunoregulation"],"prefix":"10.3389","volume":"11","author":[{"given":"Amber M.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily K.","family":"Kleczko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael A.","family":"Nemenoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e1268308","DOI":"10.1080\/2162402x.2016.1268308","article-title":"Prostaglandin E2-mediated adenosinergic effects on CD14+ cells: self-amplifying immunosuppression in cancer","volume":"6","author":"Al-Taei","year":"2017","journal-title":"OncoImmunology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.4049\/jimmunol.178.3.1628","article-title":"Synthetic prostacyclin analogs differentially regulate macrophage function via distinct analog-receptor binding specificities","volume":"178","author":"Aronoff","year":"2007","journal-title":"J. Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/jci91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Invest."},{"key":"B4","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/0009-9120(90)90255-s","article-title":"The eicosanoids: a historical overview","volume":"23","author":"Baker","year":"1990","journal-title":"Clin. Biochem."},{"key":"B5","doi-asserted-by":"publisher","first-page":"16069","DOI":"10.1074\/jbc.272.26.16069","article-title":"Function and inhibition of intracellular calcium-independent phospholipase A2","volume":"272","author":"Balsinde","year":"1997","journal-title":"J. Biol. Chem."},{"key":"B6","first-page":"356","article-title":"PGE(2) contributes to TGF-beta induced T regulatory cell function in human non-small cell lung cancer","volume":"2","author":"Baratelli","year":"2010","journal-title":"Am. J. Transl. Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.4049\/jimmunol.175.3.1483","article-title":"Prostaglandin E2 Induces FOXP3 gene expression and T regulatory cell function in human CD4+T cells","volume":"175","author":"Baratelli","year":"2005","journal-title":"J. Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.plefa.2016.01.006","article-title":"Prostaglandin D2 is a novel repressor of IFN\u03b3 induced indoleamine-2,3-dioxygenase via the DP1 receptor and cAMP pathway","volume":"110","author":"Bassal","year":"2016","journal-title":"Prostagl. Leukot. Essent. Fat. Acids"},{"key":"B9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1146\/annurev.med.53.082901.104018","article-title":"The mechanisms of action of PPARs","volume":"53","author":"Berger","year":"2002","journal-title":"Annu. Rev. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1056\/nejmoa061355","article-title":"Celecoxib for the prevention of sporadic colorectal adenomas","volume":"355","author":"Bertagnolli","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1681\/ASN.V32128","article-title":"Phospholipase A2 and signal transduction","volume":"3","author":"Bonventre","year":"1992","journal-title":"J. Am. Soc. Nephrol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e201900328","DOI":"10.26508\/lsa.201900328","article-title":"Tumor-intrinsic response to IFNgamma shapes the tumor microenvironment and anti-PD-1 response in NSCLC","volume":"2","author":"Bullock","year":"2019","journal-title":"Life Sci. Alliance"},{"key":"B14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3389\/fcell.2016.00103","article-title":"Evaluation of cysteinyl leukotriene signaling as a therapeutic target for colorectal cancer","volume":"4","author":"Burke","year":"2016","journal-title":"Front. Cell Dev. Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1189\/jlb.1212631","article-title":"At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy","volume":"94","author":"Callahan","year":"2013","journal-title":"J. Leukoc. Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41571-019-0173-9","article-title":"Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC","volume":"16","author":"Camidge","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.2174\/092986706778742963","article-title":"Cysteinyl-leukotriene receptor antagonists: present situation and future opportunities","volume":"13","author":"Capra","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/bor.0b013e328356d9f6","article-title":"Lipids and eicosanoids in fibrosis","volume":"24","author":"Castelino","year":"2012","journal-title":"Curr. Opin. Rheumatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10555-011-9324-x","article-title":"Eicosanoid signalling pathways in the development and progression of colorectal cancer: novel approaches for prevention\/intervention","volume":"30","author":"Cathcart","year":"2011","journal-title":"Canc. Metastasis Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/bs.apha.2015.04.005","article-title":"Cytochrome P450-CYP2 family-epoxygenase role in inflammation and cancer","volume":"74","author":"Chen","year":"2015","journal-title":"Adv. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.4049\/jimmunol.1502376","article-title":"Chemoattractant receptors BLT1 and CXCR3 regulate antitumor immunity by facilitating CD8+ T cell migration into tumors","volume":"197","author":"Chheda","year":"2016","journal-title":"J. Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3389\/fphar.2020.00819","article-title":"Eicosanoids in cancer: prostaglandin E2 receptor 4 in cancer therapeutics and immunotherapy","volume":"11","author":"Ching","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"7708","DOI":"10.1073\/pnas.87.19.7708","article-title":"Purification of a 110-kilodalton cytosolic phospholipase A2 from the human monocytic cell line U937","volume":"87","author":"Clark","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B24","doi-asserted-by":"publisher","first-page":"6634","DOI":"10.1158\/1078-0432.ccr-05-0436","article-title":"Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel","volume":"11","author":"Csiki","year":"2005","journal-title":"Clin. Canc. Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10555-010-9223-6","article-title":"Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity","volume":"29","author":"DeNardo","year":"2010","journal-title":"Canc. Metastasis Rev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nri3859","article-title":"Eicosanoid storm in infection and inflammation","volume":"15","author":"Dennis","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/384039a0","article-title":"The PPAR\u03b1-leukotriene B4 pathway to inflammation control","volume":"384","author":"Devchand","year":"1996","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/j.1365-2567.2007.02694.x","article-title":"Increased interleukin-10 production and Th2 skewing in the absence of 5-lipoxygenase","volume":"123","author":"DiMeo","year":"2008","journal-title":"Immunology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1158\/1078-0432.ccr-18-1538","article-title":"Immunotherapy in non-small cell lung cancer: facts and hopes","volume":"25","author":"Doroshow","year":"2019","journal-title":"Clin. Canc. Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1200\/jco.2007.13.8081","article-title":"Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy-cancer and leukemia group B trial 30203","volume":"26","author":"Edelman","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1515\/hsz-2017-0146","article-title":"Immune-regulation and -functions of eicosanoid lipid mediators","volume":"398","author":"Esser-von Bieren","year":"2017","journal-title":"Biol. Chem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"828","DOI":"10.3389\/fphar.2020.00828","article-title":"Expression and function of eicosanoid-producing cytochrome P450 enzymes in solid tumors","volume":"11","author":"Evangelista","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.coi.2013.02.009","article-title":"Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment","volume":"25","author":"Gajewski","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1016\/j.celrep.2017.08.089","article-title":"Tumor-derived mesenchymal stem cells use distinct mechanisms to block the activity of natural killer cell subsets","volume":"20","author":"Galland","year":"2017","journal-title":"Cell Rep."},{"key":"B35","doi-asserted-by":"publisher","first-page":"15359","DOI":"10.1074\/jbc.270.25.15359","article-title":"Translocation of the 85-kDa phospholipase A2from cytosol to the nuclear envelope in rat basophilic leukemia cells stimulated with calcium ionophore or IgE\/antigen","volume":"270","author":"Glover","year":"1995","journal-title":"J. Biol. Chem."},{"key":"B36","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/ni972","article-title":"Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues","volume":"4","author":"Goodarzi","year":"2003","journal-title":"Nat. Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.prostaglandins.2011.08.004","article-title":"Regulation of inflammation in cancer by eicosanoids","volume":"96","author":"Greene","year":"2011","journal-title":"Prostag. Other Lipid Mediat."},{"key":"B38","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/jnci\/42.4.663","article-title":"Growth in vitro and ultrastructure of cells from a medullary carcinoma of the human thyroid gland: transformation by simian virus 40 and evidenc of thyrocalcitonin and prostaglandins","volume":"42","author":"Grimley","year":"1969","journal-title":"J. Natl. Cancer Inst."},{"key":"B39","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/s1470-2045(04)01509-8","article-title":"Antineoplastic effects of peroxisome proliferatoractivated receptor \u03b3 agonists","volume":"5","author":"Grommes","year":"2004","journal-title":"Lancet Oncol."},{"key":"B40","doi-asserted-by":"crossref","first-page":"16645","DOI":"10.1016\/S0021-9258(18)37439-8","article-title":"Identification and characterization of a hormonally regulated form of phospholipase A2 in rat renal mesangial cells","volume":"263","author":"Gronich","year":"1988","journal-title":"J. Biol. Chem."},{"key":"B41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1042\/bj2710037","article-title":"Purification of a high-molecular-mass form of phospholipase A2 from rat kidney activated at physiological calcium concentrations","volume":"271","author":"Gronich","year":"1990","journal-title":"Biochem. J."},{"key":"B42","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B43","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat. Rev. Canc."},{"key":"B44","doi-asserted-by":"publisher","first-page":"6053","DOI":"10.2147\/ott.s204919","article-title":"EP3 receptor antagonist L798,106 reduces proliferation and migration of SK-BR-3 breast cancer cells","volume":"12","author":"Hester","year":"2019","journal-title":"OncoTargets Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1517\/14728220902915567","article-title":"Targeting the eicosanoid pathway in non-small-cell lung cancer","volume":"13","author":"Horn","year":"2009","journal-title":"Expert Opin. Ther. Targets"},{"key":"B46","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1158\/1940-6207.capr-08-0055","article-title":"NAD+-Dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer","volume":"1","author":"Hughes","year":"2008","journal-title":"Canc. Prev. Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/nejm196804182781626","article-title":"Prostaglandins and diarrhea","volume":"278","author":"Hydovitz","year":"1968","journal-title":"N. Engl. J. Med."},{"key":"B48","first-page":"5040","article-title":"The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis","volume":"60","author":"Jacoby","year":"2000","journal-title":"Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.smim.2017.09.005","article-title":"The yin and yang of leukotriene B4 mediated inflammation in cancer","volume":"33","author":"Jala","year":"","journal-title":"Semin. Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e1361593","DOI":"10.1080\/2162402x.2017.1361593","article-title":"Leukotriene B4-receptor-1 mediated host response shapes gut microbiota and controls colon tumor progression","volume":"6","author":"Jala","year":"","journal-title":"OncoImmunology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/jto.0000000000000037","article-title":"Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer","volume":"9","author":"J\u00e4nne","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e120360","DOI":"10.1172\/jci.insight.120360","article-title":"Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3\/FCRL6 engagement","volume":"3","author":"Johnson","year":"2018","journal-title":"JCI Insight"},{"key":"B53","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/bs.ai.2019.04.002","article-title":"Roles of cysteinyl leukotrienes and their receptors in immune cell-related functions","volume":"142","author":"Kanaoka","year":"2019","journal-title":"Adv. Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"10967","DOI":"10.1074\/jbc.c113.453704","article-title":"Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4Ligand","volume":"288","author":"Kanaoka","year":"2013","journal-title":"J. Biol. Chem."},{"key":"B55","first-page":"734","article-title":"Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer","volume":"62","author":"Keith","year":"2002","journal-title":"Cancer Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1158\/1940-6207.capr-11-0057","article-title":"Oral iloprost improves endobronchial dysplasia in former smokers","volume":"4","author":"Keith","year":"2011","journal-title":"Canc. Prev. Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"5897","DOI":"10.1158\/0008-5472.can-04-1070","article-title":"Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice","volume":"64","author":"Keith","year":"2004","journal-title":"Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1093\/carcin\/23.10.1653","article-title":"Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice","volume":"23","author":"Kisley","year":"2002","journal-title":"Carcinogenesis"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1007\/s10541-005-0275-0","article-title":"Lipoxygenase pathway of arachidonic acid metabolism in growth control of tumor cells of different type","volume":"70","author":"Kudryavtsev","year":"2005","journal-title":"Biochemistry (Mosc.)"},{"key":"B60","doi-asserted-by":"publisher","first-page":"16709","DOI":"10.1074\/jbc.272.27.16709","article-title":"Properties and regulation of cytosolic phospholipase A2","volume":"272","author":"Leslie","year":"1997","journal-title":"J. Biol. Chem."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e1423182","DOI":"10.1080\/2162402x.2017.1423182","article-title":"Targeted overexpression of prostacyclin synthase inhibits lung tumor progression by recruiting CD4+ T lymphocytes in tumors that express MHC class II","volume":"7","author":"Li","year":"2018","journal-title":"OncoImmunology"},{"key":"B62","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3389\/fimmu.2013.00130","article-title":"Proinflammatory and immunoregulatory roles of eicosanoids in T cells","volume":"4","author":"Lone","year":"2013","journal-title":"Front. Immunol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3390\/ijms19041019","article-title":"EP4 as a therapeutic target for aggressive human breast cancer","volume":"19","author":"Majumder","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"B64","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/s0960-9776(07)70033-4","article-title":"S10 Inflammation and breast cancer: hypothesis for targeted therapies","volume":"16","author":"Mantovani","year":"2007","journal-title":"Breast"},{"key":"B65","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/s1471-4906(02)02302-5","article-title":"Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes","volume":"23","author":"Mantovani","year":"2002","journal-title":"Trends Immunol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1172\/jci127755","article-title":"Tumor cell-intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2)","volume":"129","author":"Markosyan","year":"2019","journal-title":"J. Clin. Invest."},{"key":"B67","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.critrevonc.2018.05.012","article-title":"5-Lipoxygenase: its involvement in gastrointestinal malignancies","volume":"127","author":"Merchant","year":"2018","journal-title":"Crit. Rev. Oncol.-Hematol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1158\/1940-6207.capr-11-0233","article-title":"Chemoprevention of colon and small intestinal tumorigenesis in APCMin\/+ mice by licofelone, a novel dual 5-LOX\/COX inhibitor: potential implications for human colon cancer prevention","volume":"4","author":"Mohammed","year":"2011","journal-title":"Canc. Prev. Res."},{"key":"B69","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3390\/ijms18020236","article-title":"Cross-talk between cancer cells and the tumour microenvironment: the role of the 5-lipoxygenase pathway","volume":"18","author":"Moore","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2008.07.033","article-title":"New aspects of the role of hydroxyeicosatetraenoic acids in cell growth and cancer development","volume":"77","author":"Moreno","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","article-title":"Macrophage activation and polarization: nomenclature and experimental guidelines","volume":"41","author":"Murray","year":"2014","journal-title":"Immunity"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.bbalip.2006.09.005","article-title":"Roles of cPLA2\u03b1 and arachidonic acid in cancer","volume":"1761","author":"Nakanishi","year":"2006","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1152\/physrev.1999.79.4.1193","article-title":"Prostanoid receptors: structures, properties, and functions","volume":"79","author":"Narumiya","year":"1999","journal-title":"Physiol. Rev."},{"key":"B74","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1097\/jto.0b013e318158cf0a","article-title":"Peroxisome proliferator-activated receptor-\u03b3 in lung cancer: defining specific versus \"Off-Target\u2015 effectors","volume":"2","author":"Nemenoff","year":"2007","journal-title":"J. Thorac. Oncol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.2741\/2170","article-title":"Cyclooxygenases and lipoxygenases in prostate and breast cancers","volume":"12","author":"Nie","year":"2007","journal-title":"Front. Biosci."},{"key":"B76","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/s0952-3278(03)00023-1","article-title":"Evaluation of eicosanoids and NSAIDs as PPARgamma ligands in colorectal carcinoma cells","volume":"68","author":"Nixon","year":"2003","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"B77","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/j.1365-2249.2003.02387.x","article-title":"LTB4 is present in exudative pleural effusions and contributes actively to neutrophil recruitment in the inflamed pleural space","volume":"135","author":"Pace","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1172\/JCI58128","article-title":"Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice","volume":"122","author":"Panigrahy","year":"2012","journal-title":"J. Clin. Invest."},{"key":"B79","doi-asserted-by":"publisher","first-page":"687","DOI":"10.4161\/cbt.4.7.2014","article-title":"PPARgamma as a therapeutic target for tumor angiogenesis and metastasis","volume":"4","author":"Panigrahy","year":"2005","journal-title":"Canc. Biol. Ther."},{"key":"B80","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s10555-011-9315-y","article-title":"EET signaling in cancer","volume":"30","author":"Panigrahy","year":"2011","journal-title":"Canc. Metastasis Rev."},{"key":"B81","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Canc."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.4049\/jimmunol.1502364","article-title":"Expression profiling of macrophages reveals multiple populations with distinct biological roles in an immunocompetent orthotopic model of lung cancer","volume":"196","author":"Poczobutt","year":"","journal-title":"J. Immunol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"891","DOI":"10.4049\/jimmunol.1501648","article-title":"Deletion of 5-lipoxygenase in the tumor microenvironment promotes lung cancer progression and metastasis through regulating T cell recruitment","volume":"196","author":"Poczobutt","year":"","journal-title":"J. Immunol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"e79633","DOI":"10.1371\/journal.pone.0079633","article-title":"Eicosanoid profiling in an orthotopic model of lung cancer progression by mass spectrometry demonstrates selective production of leukotrienes by inflammatory cells of the microenvironment","volume":"8","author":"Poczobutt","year":"2013","journal-title":"PloS One"},{"key":"B85","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1158\/0008-5472.can-19-2843","article-title":"Tumor-derived prostaglandin E2 promotes p50 NF-\u03baB-Dependent differentiation of monocytic MDSCs","volume":"80","author":"Porta","year":"2020","journal-title":"Cancer Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1073\/pnas.1612920114","article-title":"COX2\/mPGES1\/PGE2pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells","volume":"114","author":"Prima","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B87","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/s0006-2952(01)00857-7","article-title":"Is inhibition of cyclooxygenase required for the anti-tumorigenic effects of nonsteroidal, anti-inflammatory drugs (NSAIDs)?","volume":"63","author":"Raz","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"857","DOI":"10.4049\/jimmunol.1700609","article-title":"Apoptotic cancer cells suppress 5-lipoxygenase in tumor-associated macrophages","volume":"200","author":"Ringleb","year":"2018","journal-title":"J. Immunol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/carcin\/19.8.1393","article-title":"Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents","volume":"19","author":"Rioux","year":"1998","journal-title":"Carcinogenesis"},{"key":"B90","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"B91","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.celrep.2017.09.018","article-title":"Prostaglandin E2 leads to the acquisition of DNMT3A-dependent tolerogenic functions in human myeloid-derived suppressor cells","volume":"21","author":"Rodr\u00edguez-Ubreva","year":"2017","journal-title":"Cell Rep."},{"key":"B92","doi-asserted-by":"publisher","first-page":"528","DOI":"10.2310\/jim.0b013e3181659932","article-title":"Peroxisome proliferator-activated receptor \u03b3 and lung cancer biology","volume":"56","author":"Roman","year":"2008","journal-title":"J. Invest. Med."},{"key":"B93","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","article-title":"Neoantigen-directed immune escape in lung cancer evolution","volume":"567","author":"Rosenthal","year":"2019","journal-title":"Nature"},{"key":"B94","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.it.2018.11.003","article-title":"What, why, where, and when: bringing timing to immuno-oncology","volume":"40","author":"Rothschilds","year":"2019","journal-title":"Trends Immunol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"7064","DOI":"10.1038\/ncomms8064","article-title":"Crystalline silica-induced leukotriene B4-dependent inflammation promotes lung tumour growth","volume":"6","author":"Satpathy","year":"2015","journal-title":"Nat. Commun."},{"key":"B96","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.1158\/0008-5472.can-17-3977","article-title":"The cytochrome P450 slow metabolizers CYP2C9*2 and CYP2C9*3 directly regulate tumorigenesis via reduced epoxyeicosatrienoic acid production","volume":"78","author":"Sausville","year":"2018","journal-title":"Cancer Res."},{"key":"B97","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10555-011-9310-3","article-title":"Cyclooxygenases and lipoxygenases in cancer","volume":"30","author":"Schneider","year":"2011","journal-title":"Canc. Metastasis Rev."},{"key":"B98","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Canc. Cell"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B100","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.plipres.2017.04.003","article-title":"Prostaglandin synthases: molecular characterization and involvement in prostaglandin biosynthesis","volume":"66","author":"Seo","year":"2017","journal-title":"Prog. Lipid Res."},{"key":"B101","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.4049\/jimmunol.1300967","article-title":"Expression of leukotriene B4 receptor-1 on CD8+ T cells is required for their migration into tumors to elicit effective antitumor immunity","volume":"191","author":"Sharma","year":"2013","journal-title":"J. Immunol."},{"key":"B102","first-page":"362","article-title":"Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells","volume":"58","author":"Sheng","year":"1998","journal-title":"Cancer Res."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1517\/14728222.11.9.1219","article-title":"Targeting tumour-associated macrophages","volume":"11","author":"Sica","year":"2007","journal-title":"Expert Opin. Ther. Targets"},{"key":"B104","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1042\/bj2590315","article-title":"The eicosanoids and their biochemical mechanisms of action","volume":"259","author":"Smith","year":"1989","journal-title":"Biochem. J."},{"key":"B105","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3389\/fphar.2010.00143","article-title":"5-lipoxygenase: underappreciated role of a pro-inflammatory enzyme in tumorigenesis","volume":"1","author":"Steinhilber","year":"2010","journal-title":"Front. Pharmacol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/ni970","article-title":"Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment","volume":"4","author":"Tager","year":"2003","journal-title":"Nat. Immunol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10555-011-9314-z","article-title":"Prostaglandin catabolic enzymes as tumor suppressors","volume":"30","author":"Tai","year":"2011","journal-title":"Canc. Metastasis Rev."},{"key":"B108","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/annonc\/mdx755","article-title":"Comprehensive analysis of the clinical immuno-oncology landscape","volume":"29","author":"Tang","year":"2018","journal-title":"Ann. Oncol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression - implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.bbrc.2005.07.166","article-title":"LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways","volume":"335","author":"Tong","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B111","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B112","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Canc. Cell"},{"key":"B113","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41467-017-00678-2","article-title":"Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis","volume":"8","author":"Trabanelli","year":"2017","journal-title":"Nat. Commun."},{"key":"B114","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","article-title":"Myeloid-derived suppressor cells coming of age","volume":"19","author":"Veglia","year":"2018","journal-title":"Nat. Immunol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41586-019-1118-2","article-title":"Fatty acid transport protein 2 reprograms neutrophils in cancer","volume":"569","author":"Veglia","year":"2019","journal-title":"Nature"},{"key":"B116","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrc2809","article-title":"Eicosanoids and cancer","volume":"10","author":"Wang","year":"2010","journal-title":"Nat. Rev. Canc."},{"key":"B117","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1172\/jci97953","article-title":"Role of prostanoids in gastrointestinal cancer","volume":"128","author":"Wang","year":"2018","journal-title":"J. Clin. Invest."},{"key":"B118","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1038\/s41388-020-1207-6","article-title":"PTGES\/PGE2 signaling links immunosuppression and lung metastasis in Gprc5a-knockout mouse model","volume":"39","author":"Wang","year":"2020","journal-title":"Oncogene"},{"key":"B119","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1158\/0008-5472.can-15-3142","article-title":"Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can Be overcome by radiotherapy","volume":"77","author":"Wang","year":"2016","journal-title":"Cancer Res."},{"key":"B120","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature16140","article-title":"Neutrophils support lung colonization of metastasis-initiating breast cancer cells","volume":"528","author":"Wculek","year":"2015","journal-title":"Nature"},{"key":"B122","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.4049\/jimmunol.1201920","article-title":"Cancer-produced metabolites of 5-lipoxygenase induce tumor-evoked regulatory B cells via peroxisome proliferator-activated receptor \u03b1","volume":"190","author":"Wejksza","year":"2013","journal-title":"J. Immunol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/onc.2014.85","article-title":"Increased metabolites of 5-lipoxygenase from hypoxic ovarian cancer cells promote tumor-associated macrophage infiltration","volume":"34","author":"Wen","year":"2015","journal-title":"Oncogene"},{"key":"B124","doi-asserted-by":"publisher","first-page":"5904","DOI":"10.1038\/onc.2008.271","article-title":"The tumor microenvironment and its role in promoting tumor growth","volume":"27","author":"Whiteside","year":"2008","journal-title":"Oncogene"},{"key":"B125","doi-asserted-by":"publisher","first-page":"5586","DOI":"10.1158\/0008-5472.can-17-3962","article-title":"A RIPK3-PGE2 circuit mediates myeloid-derived suppressor cell-potentiated colorectal carcinogenesis","volume":"78","author":"Yan","year":"2018","journal-title":"Cancer Res."},{"key":"B126","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1159\/000502076","article-title":"Synergetic effect of EP1 receptor antagonist and (-)-Epigallocatechin-3-gallate in hepatocellular carcinoma","volume":"104","author":"Yang","year":"2019","journal-title":"Pharmacology"},{"key":"B127","article-title":"Metabolomics-lipidomics of eicosanoids and docosanoids generated by phagocytes","volume-title":"Current protocols in immunology","author":"Yang","year":"2001"},{"key":"B128","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/carcin\/21.2.139","article-title":"Cyclooxygenase-2 expression in human pancreatic adenocarcinomas","volume":"21","author":"Yip-Schneider","year":"2000","journal-title":"Carcinogenesis"},{"key":"B129","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1172\/jci97946","article-title":"Leukotriene receptors as potential therapeutic targets","volume":"128","author":"Yokomizo","year":"2018","journal-title":"J. Clin. Invest."},{"key":"B130","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/bf00666103","article-title":"Eicosanoids and the immunology of cancer","volume":"13","author":"Young","year":"1994","journal-title":"Canc. Metastasis Rev."},{"key":"B131","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.molimm.2018.12.006","article-title":"Regulation of TIM-3 expression in a human T cell line by tumor-conditioned media and cyclic AMP-dependent signaling","volume":"105","author":"Yun","year":"2019","journal-title":"Mol. Immunol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","article-title":"Cyclooxygenase-dependent tumor growth through evasion of immunity","volume":"162","author":"Zelenay","year":"2015","journal-title":"Cell"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.595498\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T10:50:53Z","timestamp":1669632653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.595498\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,18]]},"references-count":132,"alternative-id":["10.3389\/fphar.2020.595498"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.595498","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,18]]},"article-number":"595498"}}